Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 678 across all filing types
Latest filing 2024-11-11 Call Transcript
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is titled 'Earnings call Transcript- Q2FY25' and contains a detailed transcript of the company's earnings conference call held on November 4, 2024. It includes management commentary on financial results, operational highlights, market performance, and a Q&A session. The text is extensive (15,000 characters) and contains substantive financial data and analysis for the quarter. This matches the definition of a Call Transcript (CT), which is a full text transcript of company conference calls such as earnings calls with Q&A. It is not an earnings release (ER) because it is a full transcript, not just key highlights. It is not an interim/quarterly report (IR) because it is not a formal financial report but a transcript of a call discussing the results. Therefore, the correct classification is CT with high confidence.
2024-11-11 English
Copy of Newspaper Publication
Regulatory Filings
2024-11-09 English
Shareholders meeting
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Postal Ballot Notice dated November 8, 2024, issued by Gland Pharma Limited. It is addressed to stock exchanges and shareholders, informing them about a postal ballot process for the appointment of a new non-executive non-independent director. The notice references relevant regulations and circulars, details the e-voting process, cut-off dates, and the appointment of a scrutinizer. It does not contain financial statements, earnings data, or management discussion but is a formal notice for shareholder voting on a corporate governance matter. This fits the category of Proxy Solicitation & Information Statement (PSI), as it is a material sent to shareholders to provide information and request votes for a meeting or resolution. The document length is substantial and contains detailed procedural information, not just an announcement or brief notice. Therefore, the appropriate classification is PSI with high confidence.
2024-11-08 English
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 90% confidence The document is a letter addressed to stock exchanges notifying them of the schedule of analyst and institutional investor meetings. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and provides dates and participants for upcoming meetings. There is no financial data, no report attached or published, and the document is short (1661 characters). It is an announcement of meetings with investors and analysts, which fits the definition of an Investor Presentation (IP) as it focuses on investor relations activities and company engagement with financial stakeholders. Therefore, the document is best classified as an Investor Presentation (IP).
2024-11-08 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice dated November 6, 2024, addressed to stock exchanges regarding the schedule of analyst and institutional investor meetings. It references compliance with SEBI Listing Obligations and Disclosure Requirements but does not contain any financial data, report content, or detailed presentation materials. The document is an announcement of upcoming meetings rather than a report or presentation itself. It is brief (1532 characters) and serves as an informational notice to the exchanges and public. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-11-06 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the publication of a newspaper advertisement for the company's un-audited financial results for Q2 FY25. It references Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, which mandates disclosure of financial results via advertisements. The document includes copies of the newspaper advertisements but does not contain the actual financial statements or detailed financial analysis. The document length is 1767 characters, which is relatively short and primarily serves as an announcement of the publication of financial results rather than the results themselves. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement related to financial results disclosure but does not contain the full interim or quarterly report itself.
2024-11-05 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.